Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two investor conferences. The first is a fireside chat at the Credit Suisse Healthcare Conference on November 9, 2022, at 1:25 p.m. ET in Ranch Palos Verdes, CA. The second will be at the Jefferies Global Healthcare Conference in London on November 16, 2022, at 3:15 p.m. GMT. Audio webcasts of both events will be available on Kura's website, along with archived replays.
Kura Oncology focuses on precision medicines for cancer treatment, with several clinical trials ongoing, including for ziftomenib and tipifarnib.
- None.
- None.
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences:
- A fireside chat at the Credit Suisse Healthcare Conference in Ranch Palos Verdes, Calif. at 1:25 p.m. ET / 10:25 a.m. PT on November 9, 2022; and
- A fireside chat at the Jefferies Global Healthcare Conference in London at 3:15 p.m. GMT / 10:15 a.m. ET / 7:15 a.m. PT on November 16, 2022.
Audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company has also initiated a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-naïve, locally advanced/metastatic, EGFR mutant non-small cell lung cancer. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura’s website at www.kuraoncology.com.
Contacts
Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com
Media:
Jason Spark
Managing Director
Evoke Canale
(619) 849-6005
jason.spark@evokegroup.com
FAQ
What is Kura Oncology's upcoming conference schedule?
Where can I listen to the Kura Oncology investor conference webcasts?
What is the significance of Kura's drugs Ziftomenib and Tipifarnib?
Is Kura Oncology involved in any clinical trials?
What is Kura Oncology's stock symbol?
